Korea Tries To Buffer Heavy Price Cuts With R&D Incentives, But Local And Global Pharma Up In Arms
This article was originally published in PharmAsia News
Executive Summary
TOKYO - South Korea's Ministry of Health and Welfare announced this week dual measures to drastically cut drug prices, while also committing to support Korea's innovation-focused companies through tax credits and preferential pricing
You may also be interested in...
South Korea Considers Restarting Market-based Actual Transaction Price System
Faced with opposition from pharma companies jittery over the potential for more price cuts, the Ministry of Health and Welfare is considering a market-based actual transaction pricing system, which awards institutions for buying cheaper drugs.
Hanmi Receives First Korea FDA Approval For Generic Of BMS’ Baraclude
Hanmi is the first to clear regulatory hurdles to sell the country’s best-selling hepatitis B therapy after patent expiration in 2015, though the distinction doesn’t carry the same benefits as it once did.
Korean Government Steps Up R&D Incentives For Domestic Companies And MNCs
The Korea Drug Development Fund and the Health Ministry are pursuing two separate projects, but targeting the same goal of helping R&D-focused companies.